Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.50 |
| ▸ | MET | P08581 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | SMO | Q99835 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6644382 | 0.91 | ALDH1A1 (0.46) | L3MBTL1MAPTALDH1A1SCN10AMET | |
| SCHEMBL6649434 | 0.88 | L3MBTL1 (0.68) | L3MBTL1MAPTALDH1A1SCN10AMET | |
| SCHEMBL6647784 | 0.87 | ALDH1A1 (0.52) | L3MBTL1MAPTALDH1A1SCN10ARAB9A | |
| SCHEMBL6649491 | 0.86 | SCN10A (0.50) | L3MBTL1MAPTALDH1A1SCN10ARAB9A | |
| SCHEMBL6648292 | 0.82 | SCN10A (0.47) | L3MBTL1MAPTALDH1A1SCN10AMET | |
| SCHEMBL6649755 | 0.82 | PPARG (0.49) | MAPTALDH1A1METRAB9ASMN1; SMN2 | |
| SCHEMBL6645860 | 0.82 | SCN10A (0.48) | L3MBTL1MAPTALDH1A1SCN10ARAB9A | |
| SCHEMBL6644178 | 0.81 | L3MBTL1 (0.56) | L3MBTL1MAPTALDH1A1METRAB9A | |
| SCHEMBL6646584 | 0.81 | SCN10A (0.44) | L3MBTL1MAPTALDH1A1SCN10AMET | |
| SCHEMBL6645905 | 0.81 | RAB9A (0.44) | MAPTALDH1A1METRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | L3MBTL1 1609/4885MAPT 4101/4885ALDH1A1 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.